Shandong Weigao Medical Polymer : VOLUNTARY ANNOUNCEMENT TRANSFER OF SHARES BY CONTROLLING SHAREHOLDER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

山 東 威 高 集 團 醫 用 高 分 子 製 品 股 份 有 限 公 司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

VOLUNTARY ANNOUNCEMENT

TRANSFER OF SHARES BY CONTROLLING SHAREHOLDER

This is a voluntary announcement made by Shandong Weigao Group Medical Polymer Company Limited (the "Company").

Reference is made to the voluntary announcement made by the Company dated 8 January 2020 (the "Announcement"). Capitalised terms used in this announcement shall have the same meaning as defined in the Announcement unless the context requires otherwise.

The Board of the Company was informed by Weigao Group that, in connection with the issuance of the Bonds on 16 January 2020, Top Vision will acquire on 11 February 2020 117,000,000 Shares at the price of HK$8.262 per Share, representing approximately 2.58% of the total issued Shares as at the date of this announcement, from Weigao Group. Top Vision used the net proceeds from the Sure First's issuance of the Bonds to procure the Shares.

As Top Vision is an indirect wholly owned subsidiary of Weigao Group, the transfer of Shares from Weigao Group to Top Vision (the "Share Transfer") does not change the shareholding of Weigao Group in the Company. In the future, if Shares are delivered upon exercise of the exchange option by any holder of the Bonds, the number of Shares indirectly held by Weigao Group will decrease correspondingly.

1

The Share Transfer does not constitute notifiable transactions or connected transactions of the Company under Chapter 14 and Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board does not expect the aforementioned transaction to have any significant impact on the business operations and the composition of the Board or management of the Company.

Shareholders of the Company and/or investors are advised to exercise extreme caution when dealing in the Company's securities.

By order of the Board

Shandong Weigao Group Medical Polymer Company Limited

Zhang Hua Wei

Chairman

Hong Kong, 10 February 2020

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (Executive Director)

Mr. Long Jing (Executive Director)

Mr. Wang Yi (Executive Director)

Mr. Gong Jian Bo (Executive Director)

Mrs. Zhou Shu Hua (Non-executive Director)

Mr. Lo Wai Hung (Independent non-executive Director)

Mrs. Fu Ming Zhong (Independent non-executive Director)

Mrs. Wang Jin Xia (Independent non-executive Director)

• For identification purpose only

2